101264-48-6

Basic information

• Product Name: N-BENZYLPIPERIDINE-4-CARBOXAMIDE HYDROCHLORIDE
• Synonyms: N-BENZYL-4-PIPERIDINECARBOXAMIDE HYDROCHLORIDE;N-benzylpiperidine-4-carboxamide(SALTDATA: HCl);N-Benzyl-4-piperidinecarboxamide
• CAS NO: 101264-48-6
• Molecular Formula: C₁₃H₁₈N₂O
• Molecular Weight: 254.76
• Mol File: 101264-48-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 115-117 °C
• Boiling Point: 437.2 °C at 760 mmHg
• Flash Point: 179.9 °C
• Appearance: /
• Density: 1.073 g/cm³
• Vapor Pressure: 7.64E-08mmHg at 25°C
• PKA: 15.93±0.20(Predicted)
• CAS DataBase Reference: N-BENZYLPIPERIDINE-4-CARBOXAMIDE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BENZYLPIPERIDINE-4-CARBOXAMIDE HYDROCHLORIDE(101264-48-6)
• EPA Substance Registry System: N-BENZYLPIPERIDINE-4-CARBOXAMIDE HYDROCHLORIDE(101264-48-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 101264-48-6(Hazardous Substances Data)

Usage

General Description

N-Benzylpiperidine-4-carboxamide hydrochloride is a chemical compound that is commonly used in the pharmaceutical industry. It is a derivative of piperidine and is often employed as an intermediate in the synthesis of various medications, particularly those related to the central nervous system. N-BENZYLPIPERIDINE-4-CARBOXAMIDE HYDROCHLORIDE has analgesic and anesthetic properties and is known to act as an antagonist for certain neurotransmitter receptors. It is also used in the development of new drugs for the treatment of various neurological disorders. Additionally, N-benzylpiperidine-4-carboxamide hydrochloride has potential applications in research and development for its pharmacological properties.

InChI:InChI=1/C13H18N2O/c16-13(12-6-8-14-9-7-12)15-10-11-4-2-1-3-5-11/h1-5,12,14H,6-10H2,(H,15,16)/p+1

Upstream product

• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 100-46-9 benzylamine 
• 498-94-2 isonipecotic acid 
• 1026416-11-4 4-benzylcarbamoyl-piperidine-1-carboxylic acid 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadecafluoro-1,1-dimethyl-undecyl ester 
• 6320-63-4 isonicotinic acid benzylamide 
• 350716-60-8 piperidine-1,4-dicarboxylic acid mono-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadecafluoro-1,1-dimethylundecyl) ester 
• 39546-32-2 4-carboxamidopiperidine 
• 100-39-0 benzyl bromide 
• 188527-08-4 N-(tert-butoxycarbonyl)-4-(4-phenylmethyl-amidoacetyl)piperidine 

Downstream Products

• 1043689-45-7 N-benzyl-1-(4-chlorobenzyl)piperidine-4-carboxamide 
• 1089340-05-5 N-benzyl-1-(4-methylbenzyl)piperidine-4-carboxamide 
• 1242436-68-5 1-[3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-propyl]-piperidine-4-carboxylic acid benzylamide 
• 177948-71-9 4-(benzylaminomethyl)piperidine 
• 1401619-10-0 N-benzyl-1-(1-(4-chlorobenzyl)-3-methyl-1H-indole-2-carbonyl)piperidine-4-carboxamide 
• 1401619-09-7 N-benzyl-1-(1-(4-chlorobenzyl)-7-methyl-1H-indole-2-carbonyl)piperidine-4-carboxamide 
• 1104937-24-7 1-[2-(benzyl-phenyl-amino)-1-methyl-ethyl]-piperidine-4-carboxylic acid benzylamide 
• 1104937-26-9 1-(1-methyl-3,3-diphenyl-propyl)-piperidine-4-carboxylic acid benzylamide 

Relevant articles and documents

Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity

HDAC8 has been established as one of the vital targets as far as the cancer is concerned. Different compounds having potential HDAC inhibitory activity have been approved by USFDA. However, none of these compounds are selective towards specific HDAC isoform. In this current study, some new hydroxamate derivatives with alkylpiperidine and alkylpiperazine linker moieties have been designed, synthesized and biologically evaluated. All these compounds are effective HDAC8 inhibitors comprising more or less similar cytotoxic potential against different cancer cell lines. It is observed that the piperazine scaffold containing compound is more active than the compound with piperidine scaffold for exerting HDAC8 inhibitory activity. Moreover, the 4-quinolyl cap group is better than the biphenyl group which is better than the benzyl group for producing higher HDAC8 inhibition as well as cytotoxicity. These compounds displayed selective HDAC8 inhibition over HDAC3. Moreover, these compounds showed an increased caspase3/7 activity suggesting their anticancer potential through modulation of apoptotic pathways. Molecular docking study with three potent compounds was performed with both HDAC3 and HDAC8 enzymes to understand the selectivity profile of these compounds. Compound containing 4-quinolyl cap group with alkyl piperazinyl urea linker moiety has been emerged out as the lead molecule that may be further modified to design more effective and selective HDAC8 inhibitors in future.

Design, synthesis, and biological evaluation of novel piperidine-4- carboxamide derivatives as potent CCR5 inhibitors

Based on a putative 'Y shape' pharmacophore model of CCR5 inhibitors, a series of novel piperidine-4-carboxamide derivatives were designed and synthesized using a group-reverse strategy. Among synthesized target compounds, 16g (IC50 = 25.73 nM) and 16i (IC50 = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC50 = 25.43 nM) in calcium mobilization assay. Selected compounds were further tested for their antiviral activity in HIV-1 single cycle assay. Two compounds, 16g and 16i, displayed antiviral activity with IC 50 values of 73.01 nM and 94.10 nM, respectively. Additionally, the pharmacokinetic properties and inhibitory potency against hERG of 16g were evaluated, providing a foundation for ongoing optimization.

Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl] piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An allosteric muscarinic M 1 receptor agonist with unprecedented selectivity and procognitive potential

The discovery and Structure-activity relationship (SAR) of a series of allosteric muscarinic M1 receptor agonists are described. Compound 17 (Lu AE51090) was identified as a representative compound from the series, based on its high selectivity as an agonist at the muscarinic M1 receptor across a panel of muscarinic receptor subtypes. Furthermore, 17 displayed a high degree of selectivity when tested in a broad panel of G-protein-coupled receptors, ion channels, transporters, and enzymes, and 17 showed an acceptable pharmacokinetic profile and sufficient brain exposure in rodents in order to characterize the compound in vivo. Hence, in a rodent model of learning and memory, 17 reversed delay-induced natural forgetting, suggesting a procognitive potential of 17.